April 13th, 2016
12:00 PM EST
Michael Grunkin, Ph.D.
Chief Executive Officer
In collaboration with Visiopharm®, Dynamyx™ software provides pathologists sophisticated tools that incorporate precision, quantification and confidence in decision-making for breast panel analysis (HER2, ER, PR, Ki67). These algorithms give pathologists additional insights when evaluating cancerous breast tissue, helping to standardize data and produce concise and consistent results. By including algorithms in their workflow, pathologists can help:
- Impact precision with easy capture and objective scoring of breast panel markers.
- Add consistency and reproducibility to their evaluation methodology.
- Provide consistent results that are easy to understand and read by the care team.
The complexity of cancer demands next generation tools. With the addition of these enhanced tools, pathologist can provide insights and detailed information to help deliver transformative patient care.
To learn more—sign up for our webinar today!
The material presented in the advertised webinar is informational only.
The results expressed in this document may not be applicable to a particular site or installation and individual results may vary. This document and its contents are provided to you for informational purposes only and do not constitute a representation, warranty or performance guarantee from GE Healthcare and Omnyx, LLC.
Omnyx is a 50:50 joint venture of GE Healthcare and UPMC.
Category: Anatomic Pathology, Clinical Laboratories, Device Manufacturers, Digital Pathology News, Education, Image Analysis, Informatics, International, Laboratory Informatics, Laboratory Management & Operations, Marketing, Web/Tech, Webinars, Whole slide